Iniparib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Peritoneal Cancer
Conditions
Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Trial Timeline
Jun 1, 2008 → Dec 1, 2008
NCT ID
NCT00677079About Iniparib
Iniparib is a phase 2 stage product being developed by Sanofi for Primary Peritoneal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00677079. Target conditions include Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Primary Peritoneal Cancer were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01130259 | Pre-clinical | Completed |
| NCT01161836 | Phase 1 | Completed |
| NCT00677079 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Peritoneal Cancer